Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,849 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Corticosteroid use in indeterminate acute liver failure.
Fujiwara K, Yasui S, Kondo T, Kato N. Fujiwara K, et al. Among authors: kato n. Liver Int. 2022 May;42(5):1209. doi: 10.1111/liv.15220. Epub 2022 Mar 3. Liver Int. 2022. PMID: 35230744 No abstract available.
Twenty-four weeks of interferon alpha-2b in combination with ribavirin for Japanese hepatitis C patients: sufficient treatment period for patients with genotype 2 but not for patients with genotype 1.
Fujiwara K, Yokosuka O, Komine F, Moriyama M, Kato N, Yoshida H, Tanaka N, Imazeki F, Shiratori Y, Arakawa Y, Omata M; Tokyo Hepatitis Network. Fujiwara K, et al. Among authors: kato n. Liver Int. 2006 Jun;26(5):520-8. doi: 10.1111/j.1478-3231.2006.01263.x. Liver Int. 2006. PMID: 16761995 Clinical Trial.
Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV NS3/4A Inhibitors.
Kanda T, Yasui S, Nakamura M, Suzuki E, Arai M, Ooka Y, Ogasawara S, Chiba T, Saito T, Haga Y, Takahashi K, Sasaki R, Wu S, Nakamoto S, Tawada A, Maruyama H, Imazeki F, Kato N, Yokosuka O. Kanda T, et al. Among authors: kato n. Int J Mol Sci. 2017 Apr 25;18(5):906. doi: 10.3390/ijms18050906. Int J Mol Sci. 2017. PMID: 28441362 Free PMC article.
Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment.
Ogasawara S, Chiba T, Ooka Y, Suzuki E, Maeda T, Yokoyama M, Wakamatsu T, Inoue M, Saito T, Kobayashi K, Kiyono S, Nakamura M, Nakamoto S, Yasui S, Tawada A, Arai M, Kanda T, Maruyama H, Yokosuka O, Kato N. Ogasawara S, et al. Among authors: kato n. Invest New Drugs. 2018 Apr;36(2):332-339. doi: 10.1007/s10637-017-0507-3. Epub 2017 Sep 11. Invest New Drugs. 2018. PMID: 28891038
Immunohistochemical analysis of IMP3 and p53 expression in endoscopic ultrasound-guided fine needle aspiration and resected specimens of pancreatic diseases.
Senoo J, Mikata R, Kishimoto T, Hayashi M, Kusakabe Y, Yasui S, Yamato M, Ohyama H, Sugiyama H, Tsuyuguchi T, Yoshitomi H, Ohtsuka M, Maeda J, Ota S, Nakatani Y, Kato N. Senoo J, et al. Among authors: kato n. Pancreatology. 2018 Mar;18(2):176-183. doi: 10.1016/j.pan.2017.12.010. Epub 2017 Dec 26. Pancreatology. 2018. PMID: 29305088
3,849 results